IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 42 filers reported holding IMMUNOVANT INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $43,935,809 | +97.9% | 1,144,334 | -2.2% | 0.01% | +66.7% |
Q2 2023 | $22,204,827 | +36.5% | 1,170,523 | +11.6% | 0.00% | +50.0% |
Q1 2023 | $16,265,621 | +91213.2% | 1,048,718 | +4.5% | 0.00% | 0.0% |
Q4 2022 | $17,813 | -99.6% | 1,003,595 | +23.3% | 0.00% | +100.0% |
Q3 2022 | $4,540,000 | +46.5% | 813,669 | +2.4% | 0.00% | – |
Q2 2022 | $3,100,000 | -28.7% | 794,972 | +0.8% | 0.00% | -100.0% |
Q1 2022 | $4,346,000 | -37.8% | 788,838 | -3.8% | 0.00% | 0.0% |
Q4 2021 | $6,989,000 | -6.0% | 820,399 | -4.1% | 0.00% | 0.0% |
Q3 2021 | $7,437,000 | -16.9% | 855,908 | +1.0% | 0.00% | 0.0% |
Q2 2021 | $8,953,000 | -29.8% | 847,110 | +6.5% | 0.00% | -50.0% |
Q1 2021 | $12,756,000 | -63.4% | 795,320 | +5.4% | 0.00% | -66.7% |
Q4 2020 | $34,849,000 | +77.3% | 754,490 | +35.1% | 0.01% | +50.0% |
Q3 2020 | $19,652,000 | +123.2% | 558,481 | +54.5% | 0.00% | +100.0% |
Q2 2020 | $8,804,000 | +2854.4% | 361,569 | +1785.6% | 0.00% | – |
Q1 2020 | $298,000 | – | 19,175 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |